Special Drug Use Surveillance of Alecensa Capsules in Pediatric Patients- Recurrent or refractory ALK fusion gene-positive anaplastic large cell lymphoma
Not Applicable
Recruiting
- Conditions
- Recurrent or refractory ALK fusion gene-positive anaplastic large cell lymphoma
- Registration Number
- JPRN-UMIN000039803
- Lead Sponsor
- Chugai Pharmaceutical Co. Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
>14 years old at Alecensa initiation
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method